Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,330
  • Shares Outstanding, K 119,359
  • Annual Sales, $ 8,570 K
  • Annual Income, $ -276,130 K
  • 60-Month Beta 0.69
  • Price/Sales 9.49
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ATRA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.62
  • Most Recent Earnings $-0.56 on 03/28/24
  • Latest Earnings Date 05/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 148.76% ( +15.31%)
  • Historical Volatility 76.11%
  • IV Percentile 35%
  • IV Rank 10.06%
  • IV High 1,337.57% on 01/11/24
  • IV Low 15.84% on 01/18/24
  • Put/Call Vol Ratio 100.00
  • Today's Volume 101
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 3,705
  • Open Int (30-Day) 3,509

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.62
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +48.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6110 +13.21%
on 03/19/24
0.8325 -16.91%
on 04/04/24
+0.0961 (+16.13%)
since 03/18/24
3-Month
0.5686 +21.65%
on 01/30/24
1.5800 -56.22%
on 02/02/24
-0.0383 (-5.25%)
since 01/18/24
52-Week
0.1986 +248.29%
on 11/13/23
3.0600 -77.40%
on 04/21/23
-2.2683 (-76.63%)
since 04/18/23

Most Recent Stories

More News
Atara Biotherapeutics: Q4 Earnings Snapshot

Atara Biotherapeutics: Q4 Earnings Snapshot

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics: Q3 Earnings Snapshot

Atara Biotherapeutics: Q3 Earnings Snapshot

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Biotherapeutics: Q2 Earnings Snapshot

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -80% and 96.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ATRA : 0.6917 (-3.25%)
TFFP : 3.13 (-3.26%)
Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics: Q1 Earnings Snapshot

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 0.6917 (-3.25%)
Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Atara Biotherapeutics (ATRA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...

ATRA : 0.6917 (-3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 0.7746
2nd Resistance Point 0.7574
1st Resistance Point 0.7245
Last Price 0.6917
1st Support Level 0.6744
2nd Support Level 0.6572
3rd Support Level 0.6243

See More

52-Week High 3.0600
Fibonacci 61.8% 1.9669
Fibonacci 50% 1.6293
Fibonacci 38.2% 1.2917
Last Price 0.6917
52-Week Low 0.1986

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar